Skip to content
Press Releases

PRESS RELEASES

Date Title and Summary Additional Formats
Toggle Summary Veracyte Announces Pricing of Public Offering of 5,000,000 Shares of Common Stock
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jul. 25, 2018-- Veracyte, Inc. (Nasdaq: VCYT) today announced the pricing of an underwritten public offering of 5,000,000 shares of its common stock at a public offering price of $10.25 per share. The gross proceeds to Veracyte from this offering,
View HTML
Toggle Summary Veracyte Announces Proposed Public Offering of Common Stock
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jul. 24, 2018-- Veracyte, Inc. (Nasdaq: VCYT) today announced that it has commenced an underwritten public offering of 5,000,000 shares of its common stock. All of the shares are being offered by Veracyte .
View HTML
Toggle Summary Veracyte Announces Second Quarter 2018 Financial Results
Revenue up 24% to $22.8 Million Compared to Second Quarter 2017 Increasing Revenue and Narrowing Cash Burn Guidance for Full-year 2018 Conference Call and Webcast Today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jul. 23, 2018-- Veracyte, Inc.
View HTML
Toggle Summary Veracyte to Host Conference Call and Webcast to Discuss Second Quarter 2018 Financial Results on Monday, July 23, 2018
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jul. 9, 2018-- Veracyte, Inc. (Nasdaq: VCYT) announced today that it will report its second quarter 2018 financial results after the close of market on Monday, July 23, 2018 . Following the announcement, Veracyte will host a conference call and webcast
View HTML
Toggle Summary Veracyte Chairman and CEO to Speak at MedCity CONVERGE
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jul. 2, 2018-- Veracyte, Inc. (Nasdaq: VCYT) today announced that Bonnie Anderson , chairman and chief executive officer, will speak at the 2018 MedCity CONVERGE conference in a session entitled, “Early Diagnosis Through Predictive Biomarkers,
View HTML
Toggle Summary Veracyte Named a San Francisco Bay Area “Top Workplace” for Fifth Consecutive Year
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jun. 25, 2018-- Veracyte, Inc. (Nasdaq: VCYT) announced today that it has been awarded a 2018 Top Workplaces honor by the Bay Area News Group . This marks the fifth consecutive year that Veracyte has received this prestigious award, which is based
View HTML
Toggle Summary Veracyte to Present at the William Blair 38th Annual Growth Stock Conference
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 30, 2018-- Veracyte, Inc. (Nasdaq: VCYT) today announced that Bonnie H. Anderson , chairman and chief executive officer, will present at the William Blair 38 th Annual Growth Stock Conference on Wednesday, June 13, 2018 at 12:40 p.m.
View HTML
Toggle Summary Veracyte Announces New Study Published in JAMA Surgery Demonstrates Afirma GSC’s Ability to Significantly Reduce Unnecessary Surgeries in Thyroid Cancer Diagnosis
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 23, 2018-- Veracyte, Inc. (Nasdaq: VCYT) announced that clinical validation data published for the first time today – in JAMA Surgery – demonstrate that the next-generation Afirma Genomic Sequencing Classifier (GSC) identifies at least one third
View HTML
Toggle Summary Veracyte Announces That Data From Multiple Studies Demonstrate “Real-World” Value of Afirma Genomic Sequencing Classifier in Thyroid Cancer Diagnosis
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 19, 2018-- Veracyte, Inc. (Nasdaq: VCYT) announced that early user-experience data from three independent studies demonstrate that the next-generation Afirma Genomic Sequencing Classifier (GSC) significantly increases the number of patients who can
View HTML
Toggle Summary Veracyte Launches Early Access Program for Envisia Genomic Classifier to Improve Diagnosis of IPF
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 17, 2018-- Veracyte, Inc. (Nasdaq: VCYT) today announced that it has launched an Early Access Program to begin making the Envisia Genomic Classifier available to patients being evaluated for interstitial lung diseases (ILD), including idiopathic
View HTML